Welcome to our dedicated page for Amphastar Pharma news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharma stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a leading specialty bio-pharmaceutical company focused on complex injectable, inhalation, and intranasal products. This page provides investors and industry professionals with a centralized hub for the company’s latest news, including press releases, financial updates, and regulatory developments.
Access real-time updates on earnings reports, product approvals, manufacturing advancements, and strategic partnerships. Our curated collection ensures you stay informed about AMPH’s progress in developing high-barrier generic and proprietary pharmaceuticals across global markets.
Key updates include FDA filings, R&D milestones, and market expansion initiatives. All content is sourced directly from company communications and verified financial disclosures, providing reliable insights into operational performance and quality-driven manufacturing practices.
Bookmark this page to track Amphastar’s advancements in cGMP-compliant production, biosimilar development, and therapeutic innovations. Check back regularly for objective reporting on one of the pharmaceutical sector’s most technically adept organizations.
Amphastar Pharmaceuticals reported net revenues of $83.4 million for Q3 2020, a 4% increase year-over-year. GAAP net income rose to $3.9 million, or $0.08 per share, while adjusted non-GAAP net income reached $7.6 million, or $0.15 per share. Key contributors to revenue growth included strong sales from Primatene Mist® and the successful re-launch of the epinephrine vial. The company remains focused on product development with five ANDAs targeting $1.5 billion market and three biosimilars targeting $13 billion in the pipeline.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will announce its third quarter 2020 financial results on November 6, 2020, before market opening. A conference call will follow at 9:00 a.m. Pacific Time to discuss the results. Amphastar specializes in developing and marketing generic and proprietary injectable and inhalation products, primarily for hospital use. The company emphasizes its commitment to high-quality products with technical barriers and operates mainly through group purchasing organizations and wholesalers.
Amphastar Pharmaceuticals announced FDA approval for Atropine Sulfate injection 0.1mg/mL in a 10 mL Prefilled Syringe. This marks a significant shift from being marketed under the 'unapproved' status for 40 years, with 2019 net revenues of $12.2 million. CEO Dr. Jack Zhang emphasized that this approval addresses drug shortages and showcases Amphastar's manufacturing capabilities. The company has four ANDAs filed targeting a market size of $1.5 billion, three biosimilars worth $13 billion, and nine generics totaling $12 billion in development.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will participate in an Analyst-Moderated fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference on September 10, 2020, at 3:20 p.m. ET. Key executives, including CFO Bill Peters, will present. A live webcast will be available on Amphastar’s website and accessible for 90 days. Amphastar focuses on developing injectable and inhalation products, primarily for hospital settings. The company sells insulin active pharmaceutical ingredients and markets its products through wholesalers and group purchasing organizations.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will present at the BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 1:00 p.m. Eastern Time. The presentation will feature CFO Bill Peters, VP Dan Dischner, and SVP Tony Marrs. Investors can access the live webcast on Amphastar's website, which will be available for 90 days after the event. Amphastar specializes in developing and selling generic and proprietary injectable and inhalation products, primarily for hospital and urgent care settings.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will present at the Raymond James Virtual 2020 Human Healthcare Innovation Conference on June 18, 2020, at 11:40 a.m. ET. Key executives, including CFO Bill Peters, VP Dan Dischner, and SVP Tony Marrs, will participate in the event. The presentation will be available via a live webcast on Amphastar’s website, with access for 90 days post-event. Amphastar specializes in developing and marketing injectable, inhalation, and intranasal pharmaceutical products, primarily for hospital and clinical settings.
Amphastar Pharmaceuticals has received FDA approval for its Succinylcholine Chloride Injection USP (200 mg/10 mL) Multiple-Dose Vial, deemed therapeutically equivalent to Pfizer's Quelicin. This product, with an estimated annual U.S. market of $75 million, is used for muscle relaxation during surgery. The company has five ANDAs aimed at a combined market of $1.7 billion and is developing three biosimilars and nine generics targeting around $25 billion in potential sales. The approval emphasizes Amphastar's regulatory capacity.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 4:00 p.m. ET. CFO Bill Peters and VP of Corporate Communications Dan Dischner will lead the presentation, which can be accessed via a live webcast on the company's website. This presentation will remain available for 90 days. Amphastar specializes in developing, manufacturing, and marketing challenging generic and proprietary injectable, inhalation, and intranasal products, primarily for hospital or urgent care use.
Amphastar Pharmaceuticals reported first-quarter 2020 results with net revenues of $84.7 million, a 6% increase from $79.8 million in Q1 2019. GAAP net income reached $3.9 million ($0.08 per share) compared to $0.9 million ($0.02 per share) last year. Adjusted non-GAAP net income was $8.4 million ($0.17 per share), up from $4.9 million ($0.10). Strong sales were driven by Primatene® Mist, which saw a 344% increase. The company continues to develop a robust pipeline with 6 ANDAs and 3 biosimilars targeting markets totaling $24 billion.
